FDA warns shorter name of new Roche cancer drug may cause confusion(Reuters) - The Food and Drug Administration warned on Monday that using a shorter name for Roche's new breast cancer drug Kadcyla may lead to the treatment being confused with an older therapy and cause potential harm to patients. The FDA issued a warning on its website saying that some third-party publications, health information systems and websites were incorrectly using a truncated version of Kadcyla's generic name. ...
Source: FDA warns shorter name of new Roche cancer drug may cause confusion (http://news.yahoo.com/fda-warns-shorter-name-roche-cancer-drug-may-150123623.html)